Overview

Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of sirolimus by estimating the overall response rate (ORR) as assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1) in patients with metastatic dMMR solid cancer after immunotherapy (either due to disease progression or to inability to tolerate treatment).

Phase:

Phase 2

Details

Lead Sponsor:

Albert Einstein College of Medicine

Treatments:

Sirolimus